To elucidate effective and long-lasting neuroprotective strategies, we analysed a combination of mitochondrial protection and neurotrophic support in two well-defined animal models of neurodegeneration, traumatic lesion of optic nerve and complete 6-hydroxydopamine (6-OHDA) lesion of nigrostriatal pathway. Neuroprotection by BclX L , Glial cell line-derived neurotrophic factor (GDNF) or BclX L plus GDNF co-expression were studied at 2 weeks and at 6-8 weeks after lesions. In both lesion paradigms, the efficacy of this combination approach significantly differed depending on post-lesion time. We show that BclX L expression is more important for neuronal survival in the early phase after lesions, whereas GDNF-mediated neuroprotection becomes more prominent in the advanced state of neurodegeneration. BclX L expression was not sufficient to finally inhibit degeneration of deafferentiated central nervous system neurons. Long-lasting GDNF-mediated neuroprotection depended on BclX L co-expression in the traumatic lesion paradigm, but was independent of BclX L in the 6-OHDA lesion model. The results demonstrate that neuroprotection studies in animal models of neurodegenerative diseases should generally be performed over extended periods of time in order to reveal the actual potency of a therapeutic approach. Gene Therapy (2006) 13, 1569-1578.
Introduction
Breakdown of functional neuronal circuits in the central nervous system (CNS) as a consequence of neurodegenerative processes results in severe physiological and mental impairments. Neurodegenerative disorders like Alzheimer's and Parkinson's diseases affect millions of people primarily in the ageing societies of the western world. No causative treatment strategies are currently available. Owing to the inherently low regenerative capacity of the CNS, it is of highest clinical interest to halt or at least significantly postpone neuronal cell death in affected patients in order to maintain functional connections for as long as possible.
Various strategies have been pursued to inhibit neurodegeneration: early studies aimed at blocking the executioners of apoptotic cell death, cysteine proteases of the caspase family; however, no sustained neuroprotection could be achieved. [1] [2] [3] Many proapoptotic signals converge on breakdown of mitochondrial membrane potential, followed by the release of proapoptotic factors and subsequent caspase activation. 4 Thus, several studies focused at the maintenance of mitochondrial integrity by overexpression of antiapoptotic members of the Bcl-2 family of proteins. [5] [6] [7] This strategy proved to be significantly more efficient than caspase inhibition, although in long-term studies substantial neuronal cell loss was still observed. 5, 8 Neurotrophic factors used in traumatic lesion paradigms only shortly postponed neuronal degeneration. 9, 10 Glial cell line-derived neurotrophic factor (GDNF) is a promising candidate in the long-term treatment of Parkinson's disease, although recent clinical trials demonstrated divergent outcomes. [11] [12] [13] GDNF has been shown to induce re-sprouting of the lesioned nigrostriatal system and thus may have beneficial effects on deafferentiated neurons in general. 14, 15 The majority of human neurodegenerative diseases is not related to inherited mutations of specific proteins, but develops with ageing as a multifactorial pathology. This pathology is frequently characterized by features of oxidative stress 16 and axonal degeneration preceding neuronal cell loss, as demonstrated for Alzheimer's disease, 17 Parkinson's disease, 18 and Huntington's and other polyglutamine-repeat diseases. 19, 20 Experimental animal models of neurodegenerative diseases can reflect only certain aspects of the complex aetiology of respective human diseases. Thus, the evaluation of neuroprotective strategies aiming at generalized inhibition of neurodegeneration should be verified in more than one particular model system. Furthermore, sustained human therapy may necessitate targeting of multiple neurodegenerative pathways.
We have recently demonstrated that overexpression of BclX L efficiently prevented neurodegeneration in a model of traumatic axonal lesion. 5 While at 2 weeks after lesion this neuroprotection appeared to be almost complete, there was still substantial neuronal loss at 8 weeks after lesion, indicating that mitochondrial integrity alone was not sufficient for sustained inhibition of degeneration in deafferentiated CNS neurons. In the present study, we aimed at the inhibition of this ongoing degeneration by the concomitant expression of the neurotrophin GDNF together with BclX L . We show that although GDNF has little protective effect on axotomized retinal ganglion cells on its own, it potentiates the protective effect of BclX L . This synergistic effect was detectable only at 8 weeks after lesion. Attempting to generalize these results in a different lesion model, we expressed BclX L and GDNF in dopaminergic (DA) neurons of the substantia nigra. Severe oxidative stress via injection of 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle (MFB) was used to induce degeneration of the nigrostriatal projections and of DA nigral neurons. In this paradigm, we detected additive neuroprotective effects of BclX L and GDNF only at 2 weeks, whereas at 6 weeks after lesion, BclX L no longer contributed to the effective and stable neuroprotection achieved by GDNF.
Our results emphasize that combined application of neuroprotective molecules enhances the potency of neuroprotective gene transfer strategies. However, in both lesion experimental paradigms investigations performed at later time points after lesion (6-8 weeks) revealed substantially different outcomes than those obtained at 2 weeks after lesion. We conclude that studies lasting for extended periods of time are necessary to verify the actual potency of neuroprotective approaches.
Results
Efficient co-transduction of target neurons in retina and substantia nigra by two AAV-2 vectors
In order to evaluate efficient and long-lasting neuroprotective strategies, we aimed to express BclX L or GDNF, or BclX L plus GDNF in ganglion cells of the retina (RGCs) and in DA neurons of the substantia nigra pars compacta (SNpc). We constructed adeno-associated virus serotype 2 (AAV-2) viral vectors expressing either BclX L or GDNF plus a fluorescent reporter protein (Enhanced green fluorescence protein (EGFP) or DsRed2; Figure 1a ). Fluorescent reporters simplified tracing of transduced neuronal populations. After intravitreal co-injection of 1 Â 10 7 transducing units (t.u.) of each AAV-BclX L -DsRed and AAV-GDNF-EGFP, we found efficient co-transduction of RGCs in an area of 20-25% of the retina ( Figures  2a-c and 3a, b) , with the vast majority of transduced cells expressing both fluorescent reporters at similar levels. Limiting transduction of RGCs to a relatively small region of the retina allowed us to quantify RGC numbers in vector-transduced and in non-transduced areas of the same retina (Figure 3a and b). After stereotaxic co-injection of 1.5 Â 10 8 t.u. of both vectors into the substantia nigra, we also detected highly efficient coexpression from both vectors (Figure 2d-f ). Efficient transduction of DA neurons was documented by staining transduced sections for tyrosine-hydroxylase immunoreactivity, demonstrating almost complete transduction of DA neurons (Figure 2g-i) .
GDNF expression is only marginally effective in protecting retinal ganglion cells from axotomy-induced degeneration
RGCs are the only retinal population of neurons affected immediately by optic nerve axotomy. They specifically 5 In the present study, we aimed to improve neuroprotection by using a combination of mitochondrial integrity protection through BclX L and neurotrophic support through GDNF. To test for the efficacy of GDNF alone to protect RGCs from axotomy-induced degeneration, we expressed GDNF in RGCs and quantified surviving RGCs at 2 and 8 weeks after axonal lesion (see Figure 1b for details of experimental schedule and next paragraph for detailed quantification procedure). At 2 weeks after lesion, we counted 33% surviving RGCs upon GDNF expression, as compared to 18% in controls, which were either counted in the non-transduced areas of the same retina or in AAV-EGFP-transduced and axotomized retinas ( Figure 4 , Table 1 ). At 8 weeks after lesion, we detected only marginal neuroprotection of RGCs by GDNF expression (10% surviving RGCs after GDNF expression, 5% in controls). Although its neuroprotective effect was significant, GDNF alone did not mediate efficient protection from axotomy-induced neurodegeneration. However, as demonstrated for BclX L -expressing RGCs before, 5 surviving RGCs in GDNF-transduced retinas maintained their dendritic and axonal protrusions (Figure 3e and f). . Arrow points at a microglial cell that has taken up FG label by phagocytosis of RGCs. Black circle demarcates an EGFP-expressing amacrine cell not labelled by the RGC-specific FG fluorescence. FG-labelled RGCs display the typical punctate perinuclear fluorescence pattern. Only RGCs as seen in (c) or in inset of (h, k) were quantified for survival. A typical high-magnification image of an RGC transduced by AAV-GDNF, as demarcated by EGFP fluorescence (e) co-localized with FG-labelling (f), showing preserved neurites at 2 weeks after axotomy (white arrowheads). Representative FG-labelled areas of whole-mounted retinal specimens are shown at 2 weeks (g, h) and at 8 weeks (j, k) after axotomy. FG fluorescence of the untransduced retinal regions is shown in (g) at 2 weeks and in (j) at 8 weeks after axotomy. In the areas of retina where RGCs are co-transduced with AAV-BclX L and AAV-GDNF, surviving RGCs are detected by FG-labelling at 2 weeks (h) and at 8 weeks (k) after axotomy. The insets in (g-k) represent magnified images of the corresponding panel. Arrowheads point at RGCs, whereas arrows point at microglial cells distinguished by characteristic sigmoidal and ramified shape and uniform FG labelling. Scale bar: 500 mm in (a) and 100 mm in (g) -(k).
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GDNF and BclX L act synergisticaly in long-term neuroprotection of axotomized retinal ganglion cells
Despite the low efficacy of the neurotrophin GDNF in preserving RGCs from axotomy-induced degeneration, we reasoned that GDNF nonetheless may have a therapeutic effect in RGCs, which are basically protected by BclX L expression. Co-expression of BclX L and GDNF resulted in a 93% protection of RGCs from axotomy-induced degeneration at 2 weeks after lesion ( Figure 3h , Table 1 ). RGCs were unequivocally identified by their punctuate perinuclear fluorogold (FG) labelling ( Figure 3c and d) . In whole-mounted retinas, almost no infiltration of microglial cells was observed in transduced regions. In contrast, in non-transduced areas, the majority of FG has been incorporated into microglial cells, which have phagocytosed the degenerating RGCs (Figure 3g ). In microglial cells, the FG label is uniformly distributed, and these cells are also clearly identified by their sigmoid shape and ramifications. At 8 weeks after axotomy, numerous fluorescently labelled microglial cells were still obvious in the non-transduced control regions of the retinas (Figure 3j ), whereas only few such cells were detectable in the retinal area in which RGCs expressed BclX L plus GDNF. Here, the majority of FG-labelled cells were clearly identified as RGCs (Figure 3k ). Owing to the potent neuroprotection mediated by BclX L alone (89% protected RGCs), neuroprotection achieved by BclX L plus GDNF coexpression could not be considered as a statistically significant additive neuroprotective effect at 2 weeks after lesion. However, at 8 weeks after lesion, we could unequivocally document that BclX L and GDNF coexpression had synergistic (i.e., more than additive, Po0.001) neuroprotective effects. While BclX L or GDNF expression alone rescued 42 or 10% of RGCs, respectively, co-expression prevented neurodegeneration in 67% of RGCs (Figures 3k and 4 , Table 1 ). Thus, BclX Lmediated neuroprotection decreased over time but was potentiated by GDNF, although in a BclX L -dependent manner.
Evaluation of BclX L plus GDNF co-expression in the 6-OHDA-induced lesion of the nigrostriatal projection
Having confirmed the efficacy of BclX L and GDNF coexpression in the axotomy model, we sought to generalize these results in a different lesion paradigm. 6-OHDA is rapidly metabolized to toxic oxidation products and is widely used to induce degeneration of the nigrostriatal projection followed by degeneration of nigral DA neurons. The most severe neurotoxic effects are obtained by injection of 6-OHDA into the projection tract from substantia nigra to basal ganglia, the MFB. This application mode results in a complete eradication of DA terminals in the striatum and in almost complete degeneration of the nigrostriatal projections and of nigral DA cell bodies and dendrites.
The schedule of the experimental outline is given schematically in Figure 1c . Vectors were injected into the Synergistic neuroprotection by Bcl-X L and GDNF Z Shevtsova et al SNpc 3 weeks before stereotaxic application of 6-OHDA into the MFB. At 2 weeks after 6-OHDA application, apomorphine-induced rotations were counted and it was confirmed by more than six contralateral rotations per minute that all operated animals had developed a complete lesion of the nigrostriatal projections. Rats were killed at either 2 or 6 weeks after lesion and showed a complete loss of DA terminals in the striatum as confirmed by tyrosine-hydroxylase (TH)-immunostaining (Figure 5a and b) . Figure 5 TH immunoreactivity in rat brain after unilateral 6-OHDA lesion. Representative CPu (caudate-putamen) regions show the TH-IR projections of the DA neurons (a) at 3 weeks after 6-OHDA injection into MFB and (b) on contralateral (unlesioned) side. The insets in (a) and (b) depict the magnified views on the TH + fibre density in the corresponding areas. Immunohistochemical visualisation of surviving DAneurons by TH-immunostaining in AAV-transduced SNpc (c, d, f, g, i, j, l, m) at 2 and 6 weeks after the MFB lesion compared to the unlesioned side of the same animal (e, h, k, n) at 6 weeks after the lesion. The AAV-EGFP-transduced SNpc is shown at 2 and 6 weeks after 6-OHDA lesion in (c) and (d). TH + neurons transduced by AAV-BclX L are shown in (f), at 2 weeks after lesion, and in (g), at 6 weeks after lesion. The inset in (g) shows the predominant morphology of surviving DA neurons transduced by AAV-BclX L at 6 weeks after the lesion. Note that most cell bodies of the remaining TH + neurons are devoid of processes. The AAV-GDNF-transduced nigrae are shown at 2 and 6 weeks after the 6-OHDA lesion in (i) and (j); the nigrae co-transduced with AAV-GDNF and AAV-BclX L at 2 and 6 weeks after the MFB lesion are shown in (l) and (m). The inset in (j) shows the morphology of the majority of surviving DA neurons in AAV-GDNF-transduced SNpc at 6 weeks after the 6-OHDA lesion, whereas the inset in (k) depicts the native morphology of neurons in untreated SNpc. Note that the fibre density of the DA neurons protected by GDNF at 6 weeks after the 6-OHDA lesion (inset in (j)) is indistinguishable from that of unlesioned side (inset in (k)). Scale bar: 200 mm in (b) and 400 mm in (n).
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In animals injected with a control virus expressing only EGFP, 25% of nigral DA neurons survived the lesion for 2 weeks, whereas only 7% survived for 6 weeks (Figures 5c, d and 6a , Table 1 ). Care was taken to exclude TH-stained neurons of the ventral tegmental area (VTA) from counting, as these neurons were not directly affected by the lesion. BclX L overexpression promoted survival of DA neurons to 61% at 2 weeks after lesion and to 31% at 6 weeks after lesion (Table 1) . Importantly, the protective effect of BclX L was mainly restricted to the cell bodies of DA neurons, as the dense neuritic network of these neurons present under normal conditions was lost to a large extent (Figure 5f and g). It should be noted that the decrease in numbers of TH-positive neurons was accompanied by a respective decrease in numbers of neurons showing EGFP fluorescence in both EGFP-and BclX L plus EGFP-transduced SNpc. These results indicated that not only a downregulation of TH expression but a real loss of DA neurons occurred after 6-OHDA lesion in our paradigm. The rate of decrease in THpositive neuron numbers in either BclX L plus EGFPor in EGFP-transduced nigrae was similar, indicating that BclX L expression did not protect against the slowly progressive neurodegeneration at later stages after 6-OHDA intoxication (Figure 6a , Table 1 ). These results showed that no sustained neuroprotection could be achieved by Bcl-X L overexpression in this experimental paradigm.
GDNF protects DA cell bodies and dendritic protrusions from 6-OHDA toxicity At 2 weeks after 6-OHDA lesion, DA neurons in GDNFtransduced SNpc were substantially protected from degeneration in that 77% survived at this time ( Figure  5i , Table 1 ). In contrast to BclX L -mediated neuroprotection, surviving DA neurons showed a dense network of was also used to demonstrate that GDNF expression did not result in BclX L upregulation in SNpc neurons after AAV-GDNF transduction (eg). Scale bar: 50 mm.
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Z Shevtsova et al dendritic arborizations throughout the SNpc, indicating that GDNF not only protects DA cell bodies but also their processes from 6-OHDA toxicity. At 6 weeks after 6-OHDA lesion, no significant decrease in TH-positive cell numbers has taken place (76% surviving DA neurons; Figure 5j , Table 1 ), indicating that GDNF can inhibit and not only postpone 6-OHDA-induced neurodegeneration.
As it was demonstrated earlier, high levels of GDNF expression may result in disturbances of DA metabolism and aberrant sprouting of DA fibres. 21 Therefore, the GDNF expression cassette used in our vector construct did not contain transcriptional control elements, which strongly enhance transgene expression, such as the WPRE. GDNF expression levels in AAV-EGFP-and in AAV-GDNF-transduced SNpc as quantified by enzymelinked immunosorbent assay (ELISA) were 11 and 190 pg/mg, respectively. Thus, GDNF levels obtained from AAV-GDNF in this study were approximately 10 times lower than the GDNF levels shown to induce abberant sprouting of DA fibres in a recent study. 21 BclX L and GDNF co-expression has additive neuroprotective effects at 2 weeks after 6-OHDA lesion Co-expression of BclX L and GDNF resulted in almost complete protection of SNpc DA neurons from 6-OHDA toxicity at 2 weeks after lesion: 96% of DA neurons survived at this time (Figures 5l and 6a, Table 1 ). When compared to 77% surviving neurons through the expression of GDNF alone and 61% surviving neurons through the expression of BclX L alone, these data represent a statistically significant additive neuroprotective effect (Po0.001; Figure 6a ). Moreover, no obvious morphological differences were detected between unlesioned control DA neurons and DA neurons expressing BclX L plus GDNF (Figure 5l-n) .
Co-expression of BclX L with GDNF has no beneficial effect on DA neuron survival at 6 weeks after 6-OHDA lesion Although BclX L expression alone still resulted in significant neuroprotection from 6-OHDA toxicity at 6 weeks after lesion, its co-expression with GDNF at this time did not result in any additive neuroprotective effect. It rather appeared that neuroprotection at this time was exclusively mediated by GDNF, as the numbers of THpositive neurons in the GDNF group were identical to the numbers of TH-positive neurons in the GDNF plus BclX L group (Figures 5m and 6a, Table 1 ). In order to exclude any effect of 6-OHDA on BclX L expression, AAVBclX L -transduced nigrae were immunohistochemically stained for BclX L expression. In AAV-Bcl-X L -transduced DA-neurons surviving for up to 6 weeks after 6-OHDA intoxication, we detected the same level of cellular immunoreactivity for BclX L as in unlesioned controls that received AAV-BclX L but were not subjected to 6-OHDA lesion (Figure 6b-d) . In contrast, we could not detect any obvious upregulation of BclX L (Figure 6e-g ) or Bcl-2 expression (not shown) in AAV-GDNFtransduced DA-neurons. These latter results demonstrate that the long-lasting neuroprotective effect of GDNF on survival of DA neurons was independent from BclX L .
Discussion
Neurodegenerative diseases like Alzheimer's and Parkinson's diseases are characterized by slow and multifactorial progression, and potential therapeutic intervention is difficult owing to diagnosis at relatively late stages of life. After diagnosis, patients have one or more decades of life expectancy, which would necessitate a long-lasting therapeutical approach in order to halt or at least significantly postpone neurodegeneration. Any potential therapeutic benefit should thus be confirmed to be effective over extended periods of time. Furthermore, the multifactorial nature of neurodegeneration in its later stages suggests that therapeutic approaches targeting multiple neurodegenerative pathways might be necessary.
In many neurodegenerative diseases, axonal damage precedes the loss of neuronal cell bodies. [17] [18] [19] [20] This principle is at least partially recapitulated in the two animal models used in this study: both traumatically lesioned RGCs and 6-OHDA lesioned nigrostriatal neurons of SNpc are primarily affected through axonal damage, resulting in complete deafferentiation. Thus, the 6-OHDA lesion as used in this study is considered primarily a model of neuronal deafferentiation rather than a model of Parkinson's disease. Both lesion paradigms affected specific CNS neuron populations, which were selectively transduced by recombinant AAV vectors in order to express therapeutically active proteins.
Our data demonstrate that:
(i) In both lesion paradigms, BclX L overexpression was not sufficient to finally preserve neurons from degeneration, with a 50% decrease in numbers of surviving neurons at 6-8 weeks after lesions as compared to 2 weeks after lesions. Thus, maintenance of mitochondrial integrity may be essential for neuronal survival early after lesion, but appeared not to be sufficient for long-term survival of deafferentiated CNS neurons. (ii) When used in combination, BclX L and GDNF provided almost complete neuroprotection in both lesion paradigms at 2 weeks after lesion. This effect was clearly additive in the 6-OHDA model, indicating the important role for targeting multiple pathways in neurodegenerative diseases. (iii) Only at later time points after lesions (at 6-8 weeks)
it was possible to demonstrate that BclX L and GDNF exerted synergistic neuroprotective effects in the traumatic lesion paradigm, but that no such potentiative effect was detectable in the oxidative stress lesion paradigm. These data highlight the fact that the actual potency of a neuroprotective approach may be overlooked if the study design does not allow for long-term analysis.
Our results obtained in short-term experiments (i.e. analysis of neuronal survival at 2 weeks post-lesion time) correspond to previous studies demonstrating that a combination of expression of GDNF with the antiapoptotic Bcl-2 or X-linked inhibitor of apoptosis (XIAP) proteins may have additive neuroprotective effects. [22] [23] [24] [25] However, Natsume et al. 22, 23 overexpressed GDNF and Bcl-2 in lesion paradigms, which result in significantly less severe impact on the affected neuronal populations. Furthermore, these investigations were not extended to Synergistic neuroprotection by Bcl-X L and GDNF Z Shevtsova et al long-lasting post-lesion times than 2 weeks, and thus could not demonstrate whether Bcl-2 and GDNF expression may have any potentiating neuroprotective effect in later stages of neurodegeneration. The same issue holds true for the co-expression of GDNF with the caspase inhibitor XIAP, 24, 25 which was analysed at 2 weeks after lesions only. In addition, in these latter studies adenoviral vectors have been used, which could not restrict transgene expression to the target cell populations.
In our present study, we have evaluated the neuroprotective properties of BclX L instead of Bcl-2 for two reasons: (i) BclX L has been shown to be more potent in inhibiting mitochondrial membrane potential breakdown than Bcl-2, 26 probably owing to its efficient targeting to mitochondria. 27 (ii) BclX L but not Bcl2 can inhibit tumour necrosis factora-activated TRAILmediated apoptotic and non-apoptotic cell death (necrosis and autophagy), 28, 29 which play important roles in several neurodegenerative paradigms. [30] [31] [32] Accordingly, in both model systems evaluated in this study, BclX L plus GDNF co-expression resulted in the most effective prevention of neurodegeneration reported so far.
While the mode of action of BclX L is well defined, 26 this does not hold true for GDNF. GDNF may exert its beneficial effects through several receptor systems, including its prototype receptors GDNF family receptor 1 (GFRa) and Ret, but also neural cell adhesion molecule (NCAM) and heparansulphate-proteoglycans like syndecan-3. 33 The low neuroprotective efficacy of GDNF expression alone on axotomized RGCs may be explained by the fact that only a small subset of RGCs expresses GFRa and Ret in the adult retina. 34 After axonal lesion, an upregulation of GFRa on RGCs has been reported. 34 Thus, RGCs initially protected from degeneration by BclX L expression may become more responsive to GDNF at later time points after lesion, resulting in synergistic neuroprotection depending on receptor upregulation in advanced stages of neurodegeneration. DA neurons of the SNpc express high levels of GDNF receptors, 35 and thus may respond to the neurotrophin without a delay. The stable and sustained protection of DA neurons and the potentiation of neuroprotection in axotomized RGCs by GDNF suggest that this molecule may serve as a potent neuroprotective agent in different paradigms of neurodegeneration, provided that appropriate receptor systems are present in affected neurons.
Taken together, we demonstrate that a combination approach of targeting different pathways of neurodegeneration simultaneously was highly effective over long term in the traumatic axonal lesion model, but only for limited time in the oxidative stress lesion model. Importantly, the actual potency of the therapeutic approach could only be revealed at late time points after lesions in both experimental paradigms, suggesting that studies aiming to define neuroprotective strategies should be generally performed over extended periods of time. These results should have important implications for the design of therapeutic neuroprotective studies.
Materials and methods
AAV-2 vectors
Viral vectors based on the AAV-2 were constructed with bi-cistronic expression cassettes as described. 36 Vector genomes contained the rat cDNA for either BclX L or for GDNF pre-pro-peptide as functional transgenes and in addition a fluorescent reporter gene (EGFP or DsRed2, Clontech, Heidelberg, Germany). All transgenes were expressed from independent human synapsin 1 gene promoters ( Figure 1a ). Vectors were propagated in 293 cells using pDG as helper plasmid, 37 and purified by iodixanol step gradient centrifugation and subsequent fast protein liquid chromatography (FPLC) on an Ä kta-FPLC system equipped with heparin-affinity columns (Amersham, Freiburg, Germany). After dialysis, genome titres were determined by quantitative PCR, purity by sodium dodecyl sulphate-gel electrophoresis and infectious titres by transduction of cultured primary hippocampal neurons. Genome particles to t.u. ratio was 25:1-35:1.
Animals
Adult female Wistar rats (250-280 g) were housed at 221C, five per cage, under standard conditions with a 12:12-h dark and light cycle. For all invasive procedures, rats were anaesthetized with chloral hydrate (0.34 mg/kg body weight). For transcardial perfusions, animal were deeply anaesthetized with a lethal overdose of chloral hydrate (0.9 mg/kg body weight). All animal procedures were performed in accordance to German guidelines for care and use of laboratory animals and to the respective European Community Council Directive 86/609/EEC.
Each experimental group consisted of five animals. AAV-EGFP-injected animals were used as controls for all experimental groups. In the retina, non-transduced regions were additionally used as an internal control. RGC counts obtained for the control vector-AAV-EGFP in the vector transduced retinal area after axotomy did not differ significantly from RGC counts obtained in the non-transduced retinal areas.
Surgical procedures
Intravitreal vector injections, unilateral axotomy of the optic nerve, and retrograde FG labelling of retinal ganglion cells (RGCs) was performed essentially as described. 5 Transduction of 20-25% of the retinal area was achieved by injection of a small volume of vector at low titre (2 ml containing 1 Â 10 7 t.u.) without prior removal of fluid from the intravitreal space. This application mode resulted in reduced spread of the virus in the intravitreal space and RGC transduction in a limited area only. It thus allowed for an internal control of neuroprotection in the same retinal specimen (RGC counts in transduced versus non-transduced areas; see Figure 3b ) and for clearcut visualization of the axons of transduced RGCs projecting towards the optic disc.
Vector injections into SNpc were performed using a Kopf stereotaxic device by a computer controlled microinjector pump (World Precision Instruments, Berlin, Germany). Coordinates were AP: À0.53; ML: +0.22; DV: À0.78, relative to bregma. A fine bore glass capillary (30 mm tip diameter) was used to deliver the viral suspension of 1.5 Â 10 8 t.u. of each vector in a 2 ml volume at 400 nl/min. The capillary was kept at the injection site for 2 min before and 4 min after the injection. No alterations in numbers of TH-positive neurons were observed after application of the various vectors as compared to the contralateral non-injected Synergistic neuroprotection by Bcl-X L and GDNF Z Shevtsova et al nigra. 6-OHDA lesion was performed at 3 weeks after vector inoculations by stereotaxically injecting the toxin (3 ml of freshly prepared 5 mg/ml in 0.2% ascorbic acid) into the ipsilateral MFB at coordinates AP: À0.2; ML: +0.2; DV: À0.85, relative to bregma. In order to confirm that the lesion was complete, we used apomorphine induced rotational behaviour test in all animal groups at 2 weeks after 6-OHDA application. Apomorphine was injected intraperitoneally at 0.2 mg/kg of body weight. Number of clockwise vs counter-clockwise rotations was counted at a rotational behaviour monitor (Stoelting) for 45 min.
GDNF -ELISA
Quantification of GDNF tissue levels in transduced and contralateral SNpc was determined by ELISA (GDNF E max Immunoassay System, Promega, Mannheim, Germany) according to the manufacturer's instructions. Tissue samples of SNpc were obtained from 2-mm -thick tissue slices by means of small biopsy needles with inner diameter of 2 mm.
Quantification of neuroprotection in axotomy lesion
At the respective time points after axotomy, rats (n ¼ 5 per condition) were killed by an overdose of chloral hydrate and transcardially perfused with 4% paraformaldehyde (PFA). Eyes were removed, post-fixed for 1 h in 4% PFA, and then retinas were whole-mounted on object slides embedded in Moviol. In the centre of the vector-transduced retinal area (as identified by EGFPand/or DsRed-expressing RGCs) at 2/3 retinal radius RGCs were counted in three non-overlapping 1 mm 2 areas essentially as described.
5
Quantification of neuroprotection in 6-OHDA lesion
At the respective time points after 6-OHDA injection into MFB, rats (n ¼ 5 per condition) were killed by an overdose of chloral hydrate and transcardially perfused with 4% PFA. Brains were cut on a cryostat to 18-mmthick coronal sections, which were stored at À801C until processing. After antigen retrieval (incubation in TBS (tris-buffered saline; 20 mM Tris, pH 9.0, 136 mM NaCl; at 601C for 6 h), immunofluorescent visualization of DA neurons in SNpc was performed with primary rabbit antibody against tyrosine hydroxylase (anti-TH, 1:500, Advanced ImmunoChemicals Inc., Long Beach, CA, USA; overnight incubation at 41C) followed by 1 h incubation at room temperature with secondary Cy3-conjugated goat anti-rabbit antibody (Dianova, Hamburg, Germany). TH-immunoreactive (TH-IR) cells were counted in every eighth brain section in the region anatomically correspondent to SNpc. For the unlesioned control, TH-IR cells in SNpc were counted on the contralateral to the lesion side. TH-IR cells of the VTA area were excluded from counting. To obtain the corresponding total DA cell numbers, the counted values were multiplied by 8, assuming that the average diameter of the adult rat DA-neuron is 16-18 mm.
38
Statistics RGC and TH-IR cell counts are presented as means7s.d.'s. For each time point and experimental condition, n ¼ 5 were used. For retinas, three independent fields per retina were counted, and for TH-IR cells of SNpc region at least 13 sections were counted per animal. Statistical significance was assessed by split-plot analysis of variance and alpha-adjusting for multiplicity (Bonferroni-Holm sequentially rejective procedure) and, at the 1% level, revealed Po0.001 for either BclX Lor GDNF-transduced areas vs untransduced and vs the control AAV-EGFP-transduced SNpc at all time points. Analysis of variance (factor 1 -BclX L ; factor 2 -GDNF; interaction 1/2 ¼ BclX L +GDNF) revealed that interaction was not additive (Po0.001), but more than additive ( ¼ synergistic) for retina, but not for the SNpc, where it was additive at 2 weeks, but not significant at 6 weeks after lesion when compared to the GDNF-treated group. Pairwise comparisons of values were performed by paired, one-tailed Student's t-test.
